Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Lancet Oncol. 2017 Jun 20;18(8):1061–1075. doi: 10.1016/S1470-2045(17)30416-3

Figure 3. Clinical Response to Gilteritinib (≥80mg) in FLT3-Mutation-Positive Relapsed/Refractory AML Patients.

Figure 3

Figure 3

A) Overall clinical response, by dose, in patients with FLT3-mutation-positive R/R AML.

CR, complete remission; CRi, complete remission with incomplete hematologic recovery; CRp, complete remission with incomplete platelet recovery; PR, partial remission. Composite response (CRc=CR+CRi+CRp) and overall response (ORR=CRc+PR) are noted in bold type.

B) Kaplan–Meier curve showing the overall survival of patients receiving ≤40mg gilteritinib versus ≥80mg gilteritinib.